MedTrace Logo

Anti-SARS-CoV-2 Monoclonal Antibodies for Long COVID (COVID-19)

NCT05877508 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2025-10-28

Study results available
· View outcomes & findings →

Summary

Persistent viral infection with viral reservoirs and detection of circulating spike protein after the initial acute illness is one potential pathogenic mechanism for Long COVID. This mechanism may be able to be targeted by SARS-CoV-2 monoclonal antibodies (mAbs). This trial will study the safety and efficacy of AER002 to treat individuals with Long COVID in an adult population.

Conditions

  • Long COVID
  • Post-Acute Sequela of COVID-19
  • Post-Acute COVID-19

Interventions

DRUG

AER002

Intravenous infusion of AER002

OTHER

Placebo

Placebo infusion

Sponsors & Collaborators

  • Aerium Therapeutics

    collaborator UNKNOWN

  • Patient-Led Research Collaborative

    collaborator UNKNOWN

  • PolyBio Research Foundation

    collaborator OTHER

  • Michael Peluso, MD

    lead OTHER

Principal Investigators

  • Michael J Peluso, MD · University of California, San Francisco

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-01
Primary Completion
2024-07-29
Completion
2026-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05877508 on ClinicalTrials.gov